Alert: AmEx Pharmacy voluntarily recalls 1 lot of injectable bevacizumab

Following 3 reports of syringe malfunction, AmEx Pharmacy has issued a voluntary nationwide recall of 1 lot of 31-gauge syringes containing bevacizumab (1.25 mg/0.05 ml).

The Monoject syringe may become difficult to express, the company noted in a press release. Applying additional force while the needle is in the eye may injure the patient. So far, 2 of the 3 reports have led to an adverse drug event.

The affected lot—190212AB, BUD 5/13/2019—was distributed to ophthalmology clinics in Pennsylvania, Illinois, Texas, Wisconsin, Kansas, Tennessee, Indiana and Arizona. The lot number 190212AB appears prominently on all labeling.

AmEx Pharmacy is notifying its consignees by telephone and overnight mail, and is arranging for the return/replacement of all recalled products. Physicians should stop use of the recalled lot and return it immediately to AmEx Pharmacy.

Consumers with questions regarding this recall can contact AmEx Pharmacy at 1-800-644-9431 or by email at pharmacist@amexpharmacy.com from 9 a.m. to 6 p.m. ET, Monday through Friday.

Physicians and patients can report adverse reactions or quality issues to the FDA's MedWatch Adverse Event Reporting program:

• Online: Report adverse reactions or quality problems to the FDA’s MedWatch Adverse Event Reporting
• Mail or fax: Download the reporting form or call 1-800-332-1088 to request one. Complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178